Toonaangevende leiders

Ali Behbahani

Leeftijd : 45

Vermogen : 81 380 USD

Belangrijkste bedrijven :

CRISPR Therapeutics AG -

Arcellx, Inc. -

Monte Rosa Therapeutics, Inc. -

CVRx, Inc. -

Adaptimmune Therapeutics plc -

Nkarta, Inc. -

Black Diamond Therapeutics, Inc. -

Minerva Surgical, Inc.

Overzicht

Currently, Ali Behbahani occupies the position of Chairman of Nkarta, Inc. and General Partner of NEA Management Co. LLC.

He is also General Partner of New Enterprise Associates LLC and on the board of 18 other companies.

In the past he held the position of Director at Oyster Point Pharma, Inc., Analyst at Lehman Brothers Asset Management LLC, Venture Associate at Morgan Stanley Venture Partners and Consultant at The Medicines Co.

Dr. Behbahani received an undergraduate degree from Duke University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate from the University of Pennsylvania Medical Center.

Posities en verantwoordelijkheden van Ali Behbahani

Naam	Titel	Van
CRISPR Therapeutics AG (Biotechnologie & Medisch Onderzoek)	Independent Non-Executive Director	2015
Arcellx, Inc. (Biotechnologie & Medisch Onderzoek)	Independent Director	2015
Monte Rosa Therapeutics, Inc. (Biotechnologie & Medisch Onderzoek)	Independent Director	2020
CVRx, Inc. (Medische apparatuur, benodigdheden & distributie)	Independent Director	2013
Adaptimmune Therapeutics plc (Biotechnologie & Medisch Onderzoek)	Independent Non-Executive Director	2014
Nkarta, Inc. (Biotechnologie & Medisch Onderzoek)	Independent Director	2015
Black Diamond Therapeutics, Inc. (Biotechnologie & Medisch Onderzoek)	Independent Director	2018
Minerva Surgical, Inc. (Medische apparatuur, benodigdheden & distributie)	Independent Director	2011
FirstLight Bio, Inc.	Director	-
Rotation Medical, Inc.	Director	-
Tune Therapeutics, Inc.	Director	-
Stablix, Inc.	Director	-
858 Therapeutics, Inc.	Director	-
Korro Bio, Inc.	Director	-
Spyglass Ophthalmics, Inc.	Director	-
Cardionomic, Inc.	Director	-
ClarVista Medical, Inc.	Director	-
Ocutherix, Inc.	Director	-
Ivantis, Inc.	Director	-
New Enterprise Associates LLC	General Partner	2007
NEA Management Co. LLC	General Partner	2007

Belangnemingen van Ali Behbahani

Naam	Aandelen	%	Totale waarde
Black Diamond Therapeutics, Inc. (BDTX) (Biotechnologie & Medisch Onderzoek)	28 004	0,077%	50 407 USD
Minerva Surgical, Inc. (UTRS) (Medische apparatuur, benodigdheden & distributie)	58 279	0,20%	12 996 USD
CRISPR Therapeutics AG (CRSP) (Biotechnologie & Medisch Onderzoek)	270	0,0003%	10 976 USD
Arcellx, Inc. (ACLX) (Biotechnologie & Medisch Onderzoek)	226	0,0005%	7 001 USD
Adaptimmune Therapeutics Plc	0	0,0000%	0 USD
Monte Rosa Therapeutics, Inc. (GLUE) (Biotechnologie & Medisch Onderzoek)	0	0,0000%	0 USD
Nkarta, Inc. (NKTX) (Biotechnologie & Medisch Onderzoek)	0	0,0000%	0 USD
Genocea Biosciences, Inc.	0	0,0000%	0 USD
CVRx, Inc. (CVRX) (Medische apparatuur, benodigdheden & distributie)	0	0,0000%	0 USD

Ali BehbahaniPersoonlijk netwerk

Naam	Verwante bedrijven
Bradley Bolzon	CRISPR Therapeutics AG Monte Rosa Therapeutics, Inc. Black Diamond Therapeutics, Inc. 858 Therapeutics, Inc.
Simeon J. George	CRISPR Therapeutics AG Nkarta, Inc.
Samarth Kulkarni	CRISPR Therapeutics AG Black Diamond Therapeutics, Inc.
Fouad Azzam	Nkarta, Inc. Rotation Medical, Inc.
Alexander Mayweg	Monte Rosa Therapeutics, Inc. Black Diamond Therapeutics, Inc.
John M. Nehra	CVRx, Inc. Minerva Surgical, Inc. Ivantis, Inc. Rotation Medical, Inc. Ocutherix, Inc. NEA Management Co. LLC
Carlo Rizzuto	858 Therapeutics, Inc. FirstLight Bio, Inc. Stablix, Inc.
Tiba Aynechi	Arcellx, Inc. Nkarta, Inc.
Kavita K. Patel	Arcellx, Inc. NEA Management Co. LLC
Kirk G. Nielsen	CVRx, Inc. Spyglass Ophthalmics, Inc.